AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04198844 — intervention group
Intervention type: DRUG
Intervention: apixaban
Description: apixaban user
Study NCT03921463 — intervention group
Intervention type: OTHER
Description: This is an observational study
Study NCT02495415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
Study NCT01774435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3342
Study NCT00693628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression shrinker
Description: Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
Study NCT04060147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally once daily
Study NCT04421508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse
Description: Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
Study NCT04421508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
Study NCT01639092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir 300mg Daily Oral
Study NCT01639092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 300mg Daily Oral
Study NCT01639092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 1 mg daily Oral
Study NCT02482090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study NCT02482090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.
Study NCT02482090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
Study NCT02482090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
Study NCT00834522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 1 mg tablets
Description: 2 x 1 mg, single dose non-fasting
Study NCT03053674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and written explanation
Description: Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
Study NCT00834522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril® 1 mg tablets
Description: 2 x 1 mg, single dose non-fasting
Study NCT02702102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: Up to 20 millicuries
Study NCT06151678 — intervention group
Intervention type: OTHER
Intervention: Pain Education
Description: Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
Study NCT00773422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
Study NCT00773422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
Study NCT00773422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05203562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction evacuation
Description: both groups underwent complete mole evacuation using suction curettage.
Study NCT05203562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction evacuation
Description: both groups underwent complete mole evacuation using suction curettage.
Study NCT05203562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
Study NCT04531605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YBank program
Description: Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
Study NCT02519491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Allen Test
Description: The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
Study NCT02519491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iphone artery assessment
Description: The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
Study NCT04064892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, \& Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
Study NCT02120937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-C Therapy
Description: Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
Study NCT03637556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DST-0509
Description: Novel iron chelator with improved absorption characteristics
Study NCT03637556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jadenu
Description: Commercial iron chelator with standard absorption characteristics
Study NCT03637556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exjade
Description: Commercial iron chelator with standard absorption characteristics
Study NCT01615198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 10 mg, 20 mg, 40 mg capsules
Study NCT01615198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
Study NCT01615198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
Study NCT01615198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg tablets
Study NCT04023539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamomum zeylanicum
Description: Capsules of 2 g cinnamomum zeylanicum orally
Study NCT04023539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT03235180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
Study NCT03235180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Elastography
Description: Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
Study NCT03235180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Vascularity
Description: Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
Study NCT03235180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE)
Description: Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
Study NCT00691119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Visualization Therapy
Description: Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
Study NCT00691119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Facilitated health education sessions, twenty minutes, five times a week for six weeks.
Study NCT02249247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIIL 284 BS tablets
Study NCT02249247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIIL 284 BS tablets
Study NCT02249247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIIL 284 BS tablets
Study NCT02249247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03157570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
Study NCT05520164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening the maternal heart sound during the invasive interventions
Description: Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
Study NCT02048241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training
Description: This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
Study NCT02048241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Management Training
Description: This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
Study NCT02048241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Weekly dispensation of pills matching Intuniv but without the active medication
Study NCT02048241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intuniv
Description: Weekly administration of medication in doses as per protocol
Study NCT02956902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician supported smartphone application intervention
Study NCT00997113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
Study NCT00997113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: alfentanil 10 ug/kg immediately prior to propofol dose
Study NCT02815826 — intervention group
Intervention type: OTHER
Intervention: Barefoot training
Description: During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
Study NCT02815826 — intervention group
Intervention type: OTHER
Intervention: Shod training
Description: Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
Study NCT02820961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDAC)
Study NCT02820961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Aromatase inhibitor
Study NCT00632580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular injection with ropivacaine
Study NCT00632580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extraarticular injection with ropivacaine
Study NCT01159262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
Study NCT01159262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Morphine
Description: Per package insert, N-PASS scores and investigator discretion.
Study NCT01252693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozarelix
Description: Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
Study NCT01252693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
Study NCT02035306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive co-oximetry haemaglobin measurement
Study NCT02767362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
Study NCT04365101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study NCT03557632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy
Description: As above.
Study NCT03557632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Drug Education
Description: As above.
Study NCT01021670 — intervention group
Intervention type: DRUG
Intervention: Dapoxetine hydrochloride
Description: One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
Study NCT01021670 — intervention group
Intervention type: OTHER
Intervention: Alternate care/non-dapoxetine hydrochloride treatment(s)
Description: As prescribed or directed
Study NCT02778815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness for Mums
Study NCT06362772 — intervention group
Intervention type: RADIATION
Intervention: Iodine-125 brachytherapy
Description: In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions.
Study NCT01324193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomegranate extracts
Description: a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
Study NCT02308722 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-fraction stereotactic body radiation therapy
Description: The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)
Study NCT02121886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous reconstruction with the parietal peritoneum
Study NCT01746017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules
Study NCT04365101 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study NCT04457388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Yoga Therapy
Description: Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
Study NCT02588001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
Study NCT02823444 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Angiography
Description: Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational.
Study NCT02821663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vocal intervention
Description: 10 x 60 min. sessions of vocal intervention
Study NCT03044574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCD
Description: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.